共 8 条
[1]
The efficiency of multi-target drugs: the network approach might help drug design[J] Péter Csermely;Vilmos ágoston;Sándor Pongor Trends in Pharmacological Sciences 2005,
[2]
Chronic treatment with duloxetine is necessary for an anxiolytic-like response in the mouse zero maze: the role of the serotonin transporter[J] Psychopharmacology 2005,
[3]
From magic bullets to designed multiple ligands[J] Richard Morphy;Corinne Kay;Zoran Rankovic Drug Discovery Today 2004,
[4]
A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease[J] Narihiro Toda;Keiko Tago;Shinji Marumoto;Kazuko Takami;Mayuko Ori;Naho Yamada;Kazuo Koyama;Shunji Naruto;Kazumi Abe;Reina Yamazaki;Takao Hara;Atsushi Aoyagi;Yasuyuki Abe;Tsugio Kaneko;Hiroshi Kogen Bioorganic & Medicinal Chemistry 2003,
[5]
STI571 (Gleevec?) as a paradigm for cancer therapy[J] Brian J. Druker Trends in Molecular Medicine 2002,
[6]
Synthesis and Activity of a New Methoxytetrahydropyran Derivative as Dual Cyclooxygenase-2/5-Lipoxygenase Inhibitor[J] Sabine Barbey;Laurence Goossens;Thierry Taverne;Joséphine Cornet;Valérie Choesmel;Céline Rouaud;Gilles Gimeno;Sylvie Yannic-Arnoult;Catherine Michaux;Caroline Charlier;Raymond Houssin;Jean-Pierre Hénichart Bioorganic & Medicinal Chemistry Letters 2002,
[7]
First dual NK 1 antagonists–serotonin reuptake inhibitors: synthesis and SAR of a new class of potential antidepressants[J] Bioorganic & Medicinal Chemistry Letters 2002,
[8]
Approach to dual-acting platelet activating factor (PAF) receptor antagonist/thromboxane synthase inhibitor (TxSI) based on the link of PAF antagonists and TxSIs[J] Masakazu Fujita;Taketsugu Seki;Haruaki Inada;Kazuhiro Shimizu;Akane Takahama;Tetsuro Sano Bioorganic & Medicinal Chemistry Letters 2002,